# A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1

> **NCT04589026** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cosentyx
- **DRUG:** Candin

## Key facts

- **NCT ID:** NCT04589026
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2021-05-06
- **Final completion:** 2021-05-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04589026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04589026, "A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04589026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*